Biometrics

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

Retrieved on: 
Tuesday, February 6, 2024

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.
  • View the full release here: https://www.businesswire.com/news/home/20240206284355/en/
    “Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally.
  • Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here .

Regula Survey: Digital Nomads Contribute to Almost a Quarter of New Business Revenue

Retrieved on: 
Tuesday, February 6, 2024

The majority of the surveyed companies are now experiencing a tangible profit impact due to the influence of digital nomads .

Key Points: 
  • The majority of the surveyed companies are now experiencing a tangible profit impact due to the influence of digital nomads .
  • “Digital nomads are shaping a brand-new segment among target audiences of both Enterprises and SMB companies across different sectors—from Banking to Travel.
  • To get the most out of attracting digital nomads whilst preventing a rise in fraud, companies need to refine their business processes, in particular IDV-related ones.
  • To learn more about the digital nomad’s impact on corporate profits, download the report “Identity Verification in a Globalized World” .

Kaizen Gaming Bets on Jumio for Winning Customer Experience

Retrieved on: 
Tuesday, February 6, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240205018204/en/
    Jumio has partnered with Kaizen Gaming to streamline its verification processes.
  • “Jumio and Kaizen Gaming have partnered while our company’s expansion project is taking place, and the KYT volumes are rapidly growing,” said Georgios Alexandros Balafoutis, Kaizen Gaming’s Senior Product Manager of Customer Account and Services.
  • Jumio’s industry-leading identity verification solutions are tailor-made for gaming, helping operators like Kaizen Gaming simplify the registration experience, detect online fraud, fight account takeover and meet compliance mandates.
  • “We’re very proud to partner with Kaizen Gaming to help them offer a more streamlined, safe and automated KYC and KYT experience to their global customer base,” said Emeka Ezeyi, Jumio’s Global Head of Gaming.

Everly Health and National Kidney Foundation Partnership Aims to Save Lives Through Early Detection of Chronic Kidney Disease

Retrieved on: 
Monday, February 5, 2024

“We are excited to partner with Everly Health to expand education on chronic kidney disease and two of its major risk factors, diabetes and hypertension,” said Joseph Vassalotti, MD, Chief Medical Officer at the National Kidney Foundation.

Key Points: 
  • “We are excited to partner with Everly Health to expand education on chronic kidney disease and two of its major risk factors, diabetes and hypertension,” said Joseph Vassalotti, MD, Chief Medical Officer at the National Kidney Foundation.
  • The new test suite includes Heart and Kidney Health Test, Diabetes Monitoring Test, Kidney Health Test, and Heart Health Test as part of preventive care screening.
  • Everly Health Solutions and a national health plan recently launched a kidney health pilot program to distribute Everly Health’s Kidney Health Tests to over 10,000 members.
  • For more information about the Everly Health Solutions diabetes monitoring and kidney health testing suite, visit https://www.everlyhealthsolutions.com/ .

biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC

Retrieved on: 
Monday, February 5, 2024

biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC).

Key Points: 
  • biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC).
  • The advanced 6-base genome data enables the exploration of epigenetic mechanisms of gene regulation through methylation and hydroxymethylation.
  • “Delivering the 6-base genome with the launch of duet evoC is a revolutionary development for researchers in the fields of oncology, neurology, ageing, and functional genomics.
  • duet evoC is advancing our mission to help scientists reveal new data and insights that will evolve solutions for early disease detection, treatment, and monitoring,” said Peter Fromen, chief executive officer at biomodal.

Eurofins Environment Testing in Sacramento, CA in Partnership with EPA Region 10 and EPA’s Office of Water Published Draft Method 1634, an Analytical Procedure to Test for 6PPD-Quinone in Surface and Stormwater

Retrieved on: 
Friday, February 2, 2024

Eurofins Environment Testing in Sacramento, California in partnership with EPA Region 10 worked with EPA’s Office of Water to publish Draft Method 1634, an analytical procedure to test for 6PPD-Quinone in surface water and stormwater.

Key Points: 
  • Eurofins Environment Testing in Sacramento, California in partnership with EPA Region 10 worked with EPA’s Office of Water to publish Draft Method 1634, an analytical procedure to test for 6PPD-Quinone in surface water and stormwater.
  • Used for more than six decades as an additive in tires, 6PPD (chemical name: N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine) is also found in other rubber products such as footwear, synthetic turf infill, and synthetic playground surfaces.
  • Exposures occur when runoff containing the chemical is washed from parking lots and streets into streams and other bodies of water.
  • With extensive experience in specialty services, Eurofins Environment Testing is proud to partner with EPA in the delivery of Draft Method 1634.

Clinical Utility of FEops AI-enabled Predictive Pre-planning for LAAO Demonstrated in US

Retrieved on: 
Friday, February 2, 2024

“This is the first-ever comprehensive clinical evaluation in the US proving that Artificial Intelligence (AI)-enabled predictive pre-planning significantly improves LAAO procedural efficiency for both the Watchman FLX and the Amulet device.

Key Points: 
  • “This is the first-ever comprehensive clinical evaluation in the US proving that Artificial Intelligence (AI)-enabled predictive pre-planning significantly improves LAAO procedural efficiency for both the Watchman FLX and the Amulet device.
  • In terms of procedural efficiency, the evaluation results revealed that in 97% cases a single LAAO device was successfully implanted with a single transseptal puncture.
  • “This real world evidence clearly reinforces the value of our pioneering digital twin strategy to alter the course of heart disease,” said Matthieu De Beule, co-founder and CEO of FEops.
  • Together we continue to advance how physicians access therapy options for patients at risk of stroke due to atrial fibrillation.

Found Advances Weight Loss Standard of Care With MetabolicPrint Launch

Retrieved on: 
Thursday, February 1, 2024

Found , one of the largest medically-assisted weight loss programs in the U.S., announced the launch of MetabolicPrint, a first-of-its-kind approach to personalized weight management care.

Key Points: 
  • Found , one of the largest medically-assisted weight loss programs in the U.S., announced the launch of MetabolicPrint, a first-of-its-kind approach to personalized weight management care.
  • Developed by Found, MetabolicPrint is a digital diagnostic support tool that uses biological and behavioral assessments to create a personalized weight health profile, or “fingerprint,” to allow care teams to tailor a corresponding precision care protocol.
  • “MetabolicPrint is about more than medication — it’s about equipping healthcare providers with individualized insights to design weight care plans that are unique to someone’s biology.
  • For more information about the science behind weight loss and strength training, check out our conversation with obé Fitness here .

Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome

Retrieved on: 
Wednesday, January 31, 2024

Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).

Key Points: 
  • Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).
  • JAG201 aims to deliver functional SHANK3 via the AAV9 vector to treat the root cause of the disease.
  • “We are pleased to receive FDA clearance to bring our investigational SHANK3 gene therapy to the clinic.
  • The pre-clinical data indicate that JAG201 may have the potential to be transformative for those suffering with the disorder,” said Joe Nolan, chief executive officer of Jaguar Gene Therapy.

Rudolf Riester GmbH Partners with Docs in Clouds TeleCare GmbH to Advance Telemedicine Solutions

Retrieved on: 
Tuesday, January 30, 2024

Rudolf Riester GmbH , a leading provider of diagnostic medical devices and telemedicine solutions, is pleased to announce a strategic collaboration with Docs in Clouds TeleCare GmbH, a prominent software solutions provider for healthcare, to integrate advanced software into Riester's telemedicine offerings.

Key Points: 
  • Rudolf Riester GmbH , a leading provider of diagnostic medical devices and telemedicine solutions, is pleased to announce a strategic collaboration with Docs in Clouds TeleCare GmbH, a prominent software solutions provider for healthcare, to integrate advanced software into Riester's telemedicine offerings.
  • "Our collaboration with Docs in Clouds demonstrates our dedication to providing state-of-the-art telemedicine solutions,” stated Irina Zhdanova, CEO of Rudolf Riester GmbH.
  • Prof. Dr. Dr. Michael Czaplik, co-founder and CEO of Docs in Clouds TeleCare GmbH, commented, "Docs in Clouds is excited to work closely with Riester.
  • The partnership between Rudolf Riester GmbH and Docs in Clouds marks a significant step forward in advancing telemedicine solutions, offering a comprehensive and integrated approach to remote healthcare services across the globe.